On Monday, March 26, 2023, David M. McCoy, Director at Ridgepost Capital, purchased 70,000 shares of RPC at a price of $7.37 each, totaling an investment of $515,900. As of Thursday, the stock is up approximately 3.1%.
On Tuesday, March 27, 2023, Tempest Therapeutics’ CEO and President, Matthew Angel, bought 231,482 shares at $2.16 each for a total of $500,001. Currently, Tempest Therapeutics shares are trading down about 4.6%, with prices as low as $1.65, 23.8% below Angel’s purchase price.
